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SIRT3 Deacetylates and Activates OPA1 To Regulate Mitochondrial
Dynamics during Stress
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Department of Surgery, University of Chicago, Chicago, Illinois, USAa; Committee of Molecular and Cellular Physiology, University of Chicago, Chicago, Illinois, USAb;
Department of Medicine, University of Chicago, Chicago, Illinois, USAc; Department of Molecular Genetics and Cell Biology, University of Chicago, Illinois, USAd;
Department of Medicine, Queen’s University, Kingston, Ontario, Canadae; Division of Biology, Howard Hughes Medical Institute, California Institute of Technology,
Pasadena, California, USAf
Mitochondrial morphology is regulated by the balance between two counteracting mitochondrial processes of fusion and fission.
There is significant evidence suggesting a stringent association betweenmorphology and bioenergetics of mitochondria. Mor-
phological alterations in mitochondria are linked to several pathological disorders, including cardiovascular diseases. The con-
sequences of stress-induced acetylation of mitochondrial proteins on the organelle morphology remain largely unexplored. Here
we report that OPA1, a mitochondrial fusion protein, was hyperacetylated in hearts under pathological stress and this posttrans-
lational modification reduced the GTPase activity of the protein. The mitochondrial deacetylase SIRT3 was capable of deacetylat-
ing OPA1 and elevating its GTPase activity. Mass spectrometry andmutagenesis analyses indicated that in SIRT3-deficient cells
OPA1 was acetylated at lysine 926 and 931 residues. Overexpression of a deacetylation-mimetic version of OPA1 recovered the
mitochondrial functions of OPA1-null cells, thus demonstrating the functional significance of K926/931 acetylation in regulat-
ing OPA1 activity. Moreover, SIRT3-dependent activation of OPA1 contributed to the preservation of mitochondrial networking
and protection of cardiomyocytes from doxorubicin-mediated cell death. In summary, these data indicated that SIRT3 promotes
mitochondrial function not only by regulating activity of metabolic enzymes, as previously reported, but also by regulating mi-
tochondrial dynamics by targeting OPA1.
Sirtuins are class III histone deacetylases (HDACs), which needNAD for their catalytic activity. They are emerging as key
regulators of diverse biological processes ranging from cellular
growth to longevity. Because of their dependency on NAD, they
are highly sensitive to themetabolic state of the cell. Themamma-
lian genome encodes seven sirtuin isoforms (SIRT1 through
SIRT7), which are localized to different subcellular compartments
and regulate a multitude of cellular functions through posttrans-
lationalmodification (PTM)of target proteins. Threemammalian
sirtuins, SIRT3, 4, and 5, are localized to mitochondria (1, 2). Of
these, SIRT3 plays amajor role in deacetylating andmodifying the
enzymatic activities of several mitochondrial proteins (1, 3). Bio-
chemical and genetic studies have demonstrated that SIRT3 pro-
tects the organism frommetabolic stress, tumorigenesis, develop-
ment of cardiac hypertrophy, and aging-associated hearing loss by
reducing the synthesis of mitochondrial reactive oxygen species
(ROS) (4–6). Earlier studies have also shown that SIRT3 expres-
sion is reduced in diabetic patients (7) and high SIRT3 expression
levels are associated with longevity in humans (8, 9).
Though a role for SIRT3 in regulating mitochondrial meta-
bolic functions is well documented, whether it can also regulate
the morphology of mitochondria is not explored. Mitochondria
are highly dynamic organelles that continually undergo fusion
and fission to maintain the quality of the mitochondrial popula-
tion (10). The equilibrium between these two antagonistic pro-
cesses determines mitochondrial morphology. In cardiac cells,
mitochondria form a highly interconnected tubular network. The
optimal balance between mitochondrial fusion and fission regu-
lates key mitochondrial functions. These include maintaining the
electrochemical gradient necessary for oxidative phosphorylation,
preserving the integrity of mitochondrial DNA (mtDNA), and
exhibiting an appropriate cellular response to apoptotic stimuli.
Alterations in fusion-fission processes are observed under both
physiologic and pathological conditions (11). The process of fu-
sion rejuvenates mitochondria bymixing their contents and helps
the cell to overcome metabolic and/or environmental stress. Fis-
sion helps to increase mitochondrial numbers and also alleviates
the cellular load of damaged mitochondria (11, 12).
Themitochondrial fusion andfission process ismediated by an
evolutionarily conserved family of dynamin-related GTPases
(10). In mammals, mitochondrial outer membrane (OM) and
inner membrane (IM) fusions are mediated through mitofusins
(Mfn1 and 2) and optic atrophy 1 (OPA1) proteins, respectively
(10, 13–15). Fission is facilitated via dynamin-related protein 1
(DRP1) and fission protein 1 (Fis1) (16, 17). Although the func-
tional importance of mitochondrial dynamics is evident from nu-
merous human diseases associated with defects in mitochondrial
fusion-fission processes (11), themolecularmechanisms involved
in the regulation of mitochondrial dynamics are not yet fully un-
derstood. Many posttranslational modifications such as phos-
phorylation, oxidation, sumoylation, andubiquitination of fusion
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and fission proteins are reported to play an important role in
regulating their activities and themitochondrial dynamics (18). A
major contributor to mitochondrial protein modifications is re-
versible lysine acetylation within a protein. A proteomic survey
revealed acetylation of nearly 20%ofmitochondrial proteins (19),
and under stress, hyperacetylation of key metabolic enzymes of
mitochondria was observed. This indicates that acetylation could
be a major regulatory adaptation governing the function of this
organelle. The mitochondrial deacetylase SIRT3, which regulates
the activity of numerousmitochondrial enzymes, is portrayed as a
mitochondrial fidelity protein (1). A role of SIRT3 in regulating
mitochondrial biogenesis via activation of the PGC1/ERR
complex has been demonstrated (20–22). However, its role in
regulating mitochondrial dynamics has never been explored.
OPA1, the GTPase anchored to the IM of mitochondria, exists
in multiple long and short isoforms and performs multiple func-
tions. Besides being an obligatory protein for the IM fusion,OPA1
is also involved inmaintaining crista structure and protecting cells
from death stimuli (23, 24). Optimum function of OPA1 depends
on its protein expression level and a coordinated balance between
its long and short isoforms (25, 26). OPA heterozygous (OPA/)
mice develop mitochondrial defects in the heart and late-onset
cardiomyopathy (27, 28). Although OPA1 was identified as an
acetylated protein by proteomic survey, a functional role of this
modification was never investigated (29). In the present study, we
report OPA1 as a direct target of SIRT3. OPA1 is hyperacetylated
under stress conditions, and this modification reduces GTPase
activity of OPA1. SIRT3 deacetylates and activates OPA1 and
thereby modulates mitochondrial dynamics.
MATERIALS AND METHODS
Antibodies. The antibodies and conjugates used in this study were anti-
OPA1 (BD Biosciences, Santa Cruz), anti-SIRT3 (Cell Signaling, Santa
Cruz), anti-Flag (Abcam, Stratagene), antiacetyllysine (Cell Signaling,
Santa Cruz), anti-SIRT5 (Orbigen), anti-FlagM2-, antihemagglutinin
(anti-HA)-agarose beads (Sigma), and anti-cMyc affinity gel (Clontech).
Antibodies for Bax, Bim, FasL, cMyc, GAPDH (glyceraldehyde-3-phos-
phate dehydrogenase), P300/CBP-associated factor (PCAF), tubulin, and
actin were purchased from Santa Cruz. All horseradish peroxidase
[HRP]-conjugated secondary antibodies for Western blots were from
Santa Cruz. Alexa Fluor 594-conjugated secondary antibodies were
bought from Invitrogen, Inc.
Plasmids and adenovirus constructs. Plasmid constructs Flag-SIRT3
and Flag-SIRT3-HY (SIRT3 catalytic mutant [MUT]) were kindly pro-
vided by Eric Verdin, University of San Francisco, CA. Flag-SIRT5 plas-
mid (plasmid 13816, deposited by Eric Verdin) and human His-SIRT3
plasmid (plasmid 13736, deposited by John Denu) were from Addgene.
Human OPA1-myc plasmid was a gift from Daniel Linseman, University
of Denver, Denver, CO. Adenovirus for mitochondrial-matrix-targeted
green fluorescent protein (mtGFP) was kindly provided by Paul Schu-
macker from Northwestern University, Evanston, IL. Empty adenovirus
(Ad.Vector) and human SIRT3 adenovirus were purchased from Vector
BioLabs, Philadelphia, PA.
Animal studies. All animal protocols were reviewed and approved by
the University of Chicago Institutional Animal Care and Use Committee.
SIRT3 knockout (SIRT3KO) mice were provided by F. W. Alt, Harvard
Medical School, Boston, MA. Transgenic mice with cardiomyocyte-spe-
cific (-myosin heavy chain [MHC] promoter) expression of C-terminal-
HA-tagged mouse full-length SIRT3 were essentially generated as de-
scribed earlier (6). Chronic infusion of angiotensin II (Ang) was done by
implanting osmotic minipumps (model 2002; Alzet) in the peritoneal
cavity ofmice as described earlier (6). To induce pressure overload hyper-
trophy, transverse aortic constriction (TAC) of ascending aorta was car-
ried out in mice as described elsewhere (30). Hearts from obese, diabetic
(db/db, leptin receptor-deficient), and their wild-type (WT) control mice
were procured from the laboratory of Christopher Rhodes, University of
Chicago, Chicago, IL.
Cell culture, transfection, and adenovirus infection. Immortalized
embryonic fibroblasts (MEFs) fromOPA1-WT andOPA1-nullmice were
generated as described elsewhere (31). Primary cultures of cardiomyo-
cytes were made from ventricles of 2-day-old neonatal rat hearts as de-
scribed earlier (32). Primary cultures for cardiac fibroblasts from adult
(12-month-old) ventricular heart tissue and for embryonic fibroblasts
from embryonic day 18 (E18) embryos of WT and SIRT3KO mice were
generated using a standard protocol. Experiments were carried out be-
tween passages 2 and 4when using primary fibroblast cultures. SIRT3WT
and KO immortalized MEFs were provided by Marcia Haigis, Harvard
Medical School, Boston, MA (33). HeLa stable cells overexpressing either
WT or HY mutant SIRT3 are described elsewhere (34). All cells were
grown inDulbecco’smodified Eagle’smedium (DMEM; Invitrogen) sup-
plemented with 1% penicillin-streptomycin and 10% fetal bovine serum
(complete growthmedium). Cells were transfected with appropriate plas-
mids using Lipofectamine 2000 transfection reagent (Invitrogen) accord-
ing to the manufacturer’s protocol. For all the adenovirus experiments,
viruses were used at a multiplicity of infection (MOI) of 100. For doxo-
rubicin (Sigma) experiments, 24 h after plating, cells were treated for 24 h
either with vehicle (0.9% saline) or with doxorubicin in serum-free me-
dium. For the ROS inhibitorN-acetyl-L-cysteine (NAC) experiment, WT
and SIRT3KOprimaryMEFswere serum starved for 24 h and then treated
with either vehicle or 5 mM NAC for 16 h in serum-free medium, and
before harvesting to immunoprecipitate OPA1, cells were treated for 1 h
with 2 M trichostatin A (TSA) (Sigma).
Electron microscopy for heart samples. Freshly harvested heart tis-
sues from mice were processed in the University of Chicago’s electron
microscopy core facility for transmission electron microscopy as per the
standard protocol. Images were taken at 300 kV with an FEI Tecnai F30
electron microscope equipped with a high-performance Gatan charge-
coupled-device (CCD) camera.
Site-directed mutagenesis and retroviral transduction. Using the
QuikChange lightning site-directed mutagenesis kit (Stratagene) and
pMSCV-OPA1 retroviral plasmid (35) or humanOPA1-myc plasmid as a
template, all the K-to-R or -Q OPA1 mutant plasmids were generated.
Retrovirus production from 293T cells and infection of immortalized
OPA-null MEFs to generate retro-OPA (rOPA) stableMEF cell lines were
done using standard protocols. Double mutant (dm) OPA1-myc plas-
mids were used for transient transfections.
Immunoblotting and immunoprecipitation analyses. Cell or heart
ventricular tissue lysates were prepared in radioimmunoprecipitation as-
say (RIPA) buffer (50 mM Tris-HCl [pH 7.5], 0.1% Nonidet P-40, 1%
Triton X-100, 150 mMNaCl, 1 mM EDTA, 100 mM phenylmethylsulfo-
nyl fluoride [PMSF], 5 mM sodium orthovanadate, 10 mM -glycerol
phosphate, and 20mMNaF and Sigma protease inhibitors). Typically, 20
to 50 g of protein lysates was used for immunoblots (IB). Immunopre-
cipitation (IP) experiments using 500 to 1,000 g of total protein lysates
were carried out using standard protocols.
Immunostaining. Cells (10,000 to 20,000) plated on glass coverslips
were used for immunostaining. Cells were infected with mito-GFP (mt-
GFP), SIRT3, or control (Ad.Vector) adenovirus (MOI, 100) as indicated
for 24 to 48 h and then immunostained as described earlier (34). Confocal
microscopy and imaging analyses were done in the digital light micros-
copy core facility of the University of Chicago.
Live-cell imaging to assess m. Confocal microscopy was per-
formed with live cells plated on glass bottom dishes (MatTek, Ashland,
MA). To monitor mitochondrial membrane potential (m), tetram-
ethyl rhodamine methyl ester (TMRM; Invitrogen), a m-dependent
cationic dye, was used for the adult WT and SIRT3KO cardiac fibroblasts
isolated from heart ventricular tissue of 12-month-old mice. These cells
were infectedwithmtGFP adenovirus at anMOIof 100 for 24 to 48 hprior
Samant et al.
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to imaging, to visualize the total mitochondrial population. TMRM was
used at a final concentration of 100 nM in complete growth medium
(DMEM–10% fetal bovine serum [FBS]) without phenol red. TMRM-
loaded live cells were maintained at 37°C, and images were acquired for 5
to 10 min with a Leica SP5 tandem scanner, a two-photon spectral con-
focal system with a 63	 oil objective and 4	 digital zoom. Emission
windows were 501 to 542 nm and 544 to 683 nm for GFP and TMRM,
respectively. Illumination was 3% for a 561-nm laser, using the resonant
scanner andHyD detector, to avoid laser toxicity to cells. Cells from six or
seven independent fields were imaged from four separate plates per geno-
type. To evaluate m, the ratio of fluorescence intensity for TMRM to
mtGFP (red/green) was estimated using Image J software for every time
point. The staining ratio was used to assess m stability during obser-
vations.
RecombinantOPA1-S1 protein purification and in vitro acetylation
assay. A short isoform of human OPA1 (splice form 1; termed here
OPA1-S1)with anN-terminal 6-histidine (His) tagwas expressed in Esch-
erichia coli BL21(DE3)/pLysS bacteria (Novagen). OPA1-S1 expression
and protein purification were essentially done as explained elsewhere
(36). His.SIRT3 was also purified similarly. Purified His-OPA1-S1 on Ni-
nitrilotriacetic acid (NTA) (His) beads (Qiagen) was acetylated by incu-
bating with either 200 ng of active p300/CBP-associated factor (PCAF)
(Millipore) or 2 g PCAF (Cayman) enzyme, 1 mM acetyl coenzyme A
(acetyl-CoA), 50 mM nicotinamide (NAM), and 50 MTSA in 1	HAT
buffer (50 mM Tris-HCl [pH 8.0], 10% glycerol, 0.1 mM EDTA, 1 mM
dithiothreitol [DTT]) for 1 h at 30°C on a rotator. In the control reaction
mixture, acetyl-CoA was omitted and 63Manacardic acid was included
to inhibit residual PCAF activity. In vitro-acetylated His-OPA1-S1 was
used for downstream applications.
In vitro deacetylation assay. In vitro-acetylated His-OPA1-S1 bound
to Ni-NTA beads was washed three times with 1	HAT buffer, twice with
1	HDACbuffer (50mMTris-HCl [pH 8.8], 50mMNaCl, 1mMMgCl2,
0.5 mM DTT, and 0.1 mg/ml of bovine serum albumin). Protein-bound
beads in the HDAC buffer were incubated with Flag-SIRT3 or His-SIRT3
protein in the absence or presence of 1.5 mMNAD for the deacetylation
assay. The reaction mixture was incubated for 2 h at 37°C on a rotator.
Flag-SIRT3 protein used in these experiments was immunoprecipitated
using Flag-tagged beads (Sigma) from overexpressing HEK293T cells.
In vitroOPA1GTPase assay.Ni-NTAbeads with bound acetylated or
deacetylated His-OPA1-S1 protein and their appropriate controls were
washed multiple times with 1	 OPA1 activity assay buffer (50 mM
HEPES [pH 7.0], 1 mMDTT). GTPase activity of bead-bound OPA1 was
estimated as described earlier (36) without addition ofNaCl or liposomes.
GTP was added to a final concentration of 100M. Concentration of free
phosphate released in the GTPase reaction at different time points was
determined using the Malachite green phosphate assay kit (Bioassay Sys-
tems) according to the manufacturer’s instructions. GTPase activity of
OPA1 immunoprecipitated fromWT and SIRT3KO immortalized MEFs
was similarly estimated.
OPA1-SIRT3 direct binding assay. For the direct-interaction experi-
ment, in vitro-translated [35S]methionine-labeled Flag-SIRT3 or Flag-
SIRT5 (TNT coupled reticulocyte lysate kit; Promega) was incubated at
4°C for 2 h on a rotator with 5 g of His-OPA1-S1 protein bound to
Ni-NTA beads. As a control, labeled Flag proteins were incubated with
Ni-NTA (His) beads alone. After five washes of NETN buffer (20 mM
Tris-HCl [pH8.0], 100mMNaCl, 1mMEDTA, and 0.5%NP-40), bound
proteins were resolved on 10% SDS-PAGE and analyzed by autoradiog-
raphy as well as immunoblotting.
ROSmeasurement by flow cytometry.ROS detectionwas done using
the CM-H2DCFDA dye (Invitrogen) according to the manufacturer’s in-
structions. For ROS induction, cells were treated for 15 min with 200M
H2O2 where indicated. Cells were acquired by FACScalibur, and results
were analyzed using FlowJo software. Values for generated ROS were cal-
culated from the mean fluorescence intensity (MFI) of cells positive for
CM-H2DCFDA staining.
MS analysis for acetylated lysine residues. Tryptic digests of the pu-
rified OPA1 protein immunoprecipitated either from SIRT3 knockout
heart lysates or from other sources were analyzed by mass spectrometry
(MS) as described elsewhere (37) at the proteomics core facility of the
University of Chicago.
TUNEL assay. Twenty-four hours after neonatal rat ventricular car-
diomyocytes (NRVM) were plated onto laminin-coated glass coverslips,
they were infected with either Ad.SIRT3 or vector alone at a MOI of 100.
Twenty-four hours after infection, cells were treated either with 100 nM
doxorubicin orwith vehicle for the next 24 h in a serum-freemedium. The
terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end la-
beling (TUNEL) reaction was performed as per the manufacturer’s in-
structions using the in situ cell death (TUNEL) detection kit from Roche
Diagnostics. TUNEL-positive cells were identified by confocal micros-
copy at an excitation wavelength of 488 nm. ProLong gold antifade re-
agent with DAPI (4=,6-diamidino-2-phenylindole; Invitrogen) was used
for staining the nuclei (blue) and mounting the coverslips. Blue nuclei
with a well-defined condensed morphology and TUNEL-positive green
staining were defined as apoptotic cells. For quantitation, five indepen-
dent fields with 50 to 100 nuclei each were counted for every image.
Copy number estimation for mitochondrial DNA. Total (nuclear
mitochondrial) DNA was extracted from different OPA1 cell lines using
the QIAamp DNAminikit (Qiagen). By real-time quantitative PCR (Ab-
solute QPCR SYBR green mix; Thermo Scientific), the mtDNA copy
number was determined relative to nuclear DNA. Primers used for the
mitochondrial gene ND1 and the nuclear gene H19 were as follows: ND1
forward primer, 5=-AATCGCCATAGCCTTCCTAACAT-3=, and reverse
primer, 5=-GGCGTCTGCAAATGGTTGTAA-3=; H19 forward primer,
5=-GTACCCACCTGTCGTCC-3=, and reverse primer, 5=-GTCCAC-
GAGACCAATGA CTG-3=. For data analysis, the CT (threshold cycle)
method was employed. Data are presented as normalized values to
mtDNA copy number fromWT-OPA1MEFs. Statistical significance was
determined by comparing the normalized values to the mtDNA copy
number from OPA1-null MEFs.
OCR measurement. Baseline oxygen consumption rate (OCR) mea-
surements were done as per themanufacturer’s instruction for cells plated
at 5 	 104 per well of XF24 Seahorse plates (Seahorse Bioscience, MA).
OCR was normalized to the total protein amount per well.
MNF. To quantify functional networking of the mitochondria, i.e.,
determine themitochondrial networking factor (MNF), cells were doubly
infected with mitochondrially targeted photoactivatable GFP (mito-PA-
GFP) adenovirus (MOI, 100) (38) and mito-Ds-Red2 baculovirus (2 l/
10,000 cells) (39). Imaging experiments were performed 48 to 72 h fol-
lowing the infections as described elsewhere (40, 41).
Statistical analysis. To compare statistical significance between two
groups, a two-tailed paired t test was employed.
RESULTS
OPA1 is hyperacetylated during cardiac stress.Defects in mito-
chondrial dynamics have been documented during development
of cardiac hypertrophy (28). We found OPA1 to be hyperacety-
lated in mouse hearts that were subjected to develop cardiac hy-
pertrophy by either angiotensin-II (Ang) infusion or transverse
aortic constriction (TAC) (Fig. 1A and B). To determine whether
OPA1 was also acetylated under pathological conditions in which
cardiac dysfunction is secondary to metabolic stress, we analyzed
OPA1 acetylation in hearts of diabetic (db/db) mice. As shown in
Fig. 1C, OPA1 was hyperacetylated in hearts of db/db mice com-
pared to their nondiabetic controls. Based on this correlation be-
tween pathological stress and OPA1 acetylation, we posited that
this PTM could be regulating the enzymatic activity of OPA1. We
thereforemeasuredGTPase activity ofOPA1 that was subjected to
acetylation by the mammalian histone acetylase (HAT) PCAF.
The acetylation status of OPA1 was confirmed by Western blot-
SIRT3 Regulates Mitochondrial Dynamics
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ting and mass spectrometry (see Fig. 3B; see also Fig. S4 in the
supplemental material). Acetylation consistently reduced GTPase
activity of OPA1 by 30 to 40% (Fig. 1D). These results thus indi-
cated that pathological stress induces acetylation ofOPA1 and this
modification reduces its GTPase activity.
SIRT3 directly binds to and deacetylates OPA1. Since SIRT3
is the major mitochondrial deacetylase whose levels are also re-
duced in failing hearts (6), we postulated that this may be the
HDAC deacetylating OPA1. We therefore examined the acetyla-
tion status of OPA1 in SIRT3 knockout (SIRT3KO) hearts. These
hearts exhibit progressive aging-associated cardiac hypertrophy
and increased ROS synthesis from mitochondria (6, 42). We
found robust acetylation of OPA1 in SIRT3KO hearts compared
to wild-type controls (Fig. 1E). To test whether SIRT3 deficiency
causes a change in OPA1 activity, we immunoprecipitated OPA1
from WT and SIRT3KO MEFs and measured its GTPase activity.
As shown in Fig. 1F and G, OPA1 obtained from SIRT3KO cells
exhibited significantly reduced GTPase activity compared to
OPA1 from WT cells. Since a moderate increase in ROS levels is
known to activate HATs, it is possible that OPA1 hyperacetylation
results from increased ROS synthesis in SIRT3KO cells. To ex-
clude this possibility, we examinedOPA1 acetylation in SIRT3KO
MEFs treated with N-acetyl cysteine (NAC), an antioxidant. NAC
treatment failed to block hyperacetylation of OPA1 in SIRT3KO
cells.However, total acetylation of proteins in thewhole-cell lysate
(WCL) was suppressed by NAC treatment, which served as a pos-
itive control (see Fig. S1A in the supplemental material). These
data thus suggested that SIRT3 is likely the enzyme deacetylating
OPA1.
To test whether SIRT3 can target OPA1 for deacetylation, we
first examined binding of proteins in a cell-free system. 35S-labeled
SIRT3 was incubated with His-tagged OPA1 (His.OPA1.S1), and
the bound proteins were pulled down with Ni-NTA (His) beads.
Another mitochondrial sirtuin, SIRT5, was used as the negative
control.We found that His-OPA1 robustly bound to radiolabeled
SIRT3 but not to SIRT5 (Fig. 2A, top panel). The blot was also
probed with antibodies specific to SIRT3, SIRT5, and OPA1 to
confirm protein specificity (Fig. 2A). This experiment demon-
strated that SIRT3 and OPA1 are capable of binding to each other
directly.
We next tested in vivo binding of SIRT3 and OPA1. Cells
(293T) were coexpressed with myc-OPA1 and Flag-SIRT3, and
immunoprecipitated proteins were analyzed by Western blot-
ting. As shown in Fig. 2B, myc-OPA1 was coprecipitated with
Flag.SIRT3 and vice versa. The validity of in vivo binding between
OPA1 and SIRT3 was verified by use of appropriate positive and
negative controls (Fig. 2C). Binding of endogenous OPA1 to
SIRT3 was examined by coimmunoprecipitating proteins from
heart lysates of WT and SIRT3KO mice. As shown in Fig. 2D,
SIRT3 was pulled down with OPA1 from WT but not from
SIRT3KO hearts. We also confirmed binding of endogenous
OPA1 to SIRT3 by use of heart lysates from transgenic mice hav-
ing cardiomyocyte-specific expression of HA-SIRT3 (see Fig. S1B
in the supplemental material). These findings demonstrated that
SIRT3 binds to OPA1 in vivo. We next tested the ability of SIRT3
to deacetylateOPA1 in vivo. OPA1was deacetylated in stableHeLa
cells expressingWT-SIRT3 but not in the SIRT3-HY catalyticmu-
tant (Fig. 2E) (34). We also confirmed SIRT3-mediated deacety-
lation ofOPA1 in a reconstitution experiment inwhich SIRT3was
overexpressed in SIRT3KOcells. The results showed reduced acet-
ylation of OPA1 in SIRT3-expressing cells compared to SIRT3-
deficient cells (Fig. 2F). Collectively, these results demonstrated
that SIRT3 binds to and deacetylates OPA1 in vivo.
SIRT3-mediated deacetylation augments GTPase activity of
OPA1 and mitochondrial fusion. To elucidate the effect of
deacetylation on enzymatic activity of OPA1, we performed an in
vitroOPA1 activity assay.His.OPA1.S1was acetylated in vitrowith
PCAF and then subjected to deacetylation with SIRT3 in the pres-
ence or absence of NAD. Acetylation inhibited OPA1 activity,
whereas incubation of OPA1 with SIRT3 significantly recovered
its GTPase activity in a NAD-dependent manner (Fig. 3A and B).
This confirmed that while acetylation reduces it, SIRT3-mediated
deacetylation enhances GTPase activity of OPA1.
Since acetylation reduced the enzymatic activity of OPA1, we
investigated whether this might lead to defective mitochondrial
dynamics in SIRT3KO cells. To assess mitochondrial fusion capa-
FIG 1 Pathological stress induces OPA1 acetylation, which reduces GTPase
activity of the enzyme. Immunoblots (IB) showing hyperacetylation of immu-
noprecipitated (IP) OPA1 during hypertrophy of the heart, induced by angio-
tensin II (Ang) infusion for 30 days (A) or by transthoracic aortic constriction
(TAC) for 6 months (B), and from hearts of 2-month-old db/db mice (C),
compared to respective wild-type (WT) controls. Ac-K, antiacetyllysine anti-
body; WCL, whole-cell lysates. (D) Reduced GTPase activity of His-OPA1.S1
protein subjected to acetylation (Ac OPA) compared to that of nonacetylated
control (CNOPA). GTP hydrolysis (100M)wasmonitored up to 3 h. Values
are means
 standard errors of the means (SEM); n 4; *, P 0.001. (E) IB
showing increased acetylation of OPA1 in SIRT3 knockout (SIRT3KO) hearts
compared to WT controls. (F) Bar graph representing GTPase activity for
OPA1 immunoprecipitated from immortalized SIRT3-WT and KO MEF ly-
sates. Values aremeans
 SEM; n 4; *, P 0.05. (G) IB showing the amount
of OPA1 protein used in the assay illustrated in panel F. IP:IgG is a negative
control for IP:OPA1.
Samant et al.
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bility, we quantified mitochondrial networking in live adult car-
diac fibroblasts isolated from 12-month-old WT and SIRT3KO
mice. Cardiac fibroblastswere coexpressedwithmito-DsRed2 and
mito-PAGFP.Mitochondrial fusion wasmonitored by photoacti-
vatingmito-PAGFP in the selected region of cells (40, 41). Spread-
ing of activated GFP through the mitochondrial network was sig-
nificantly restricted to a limited area in SIRT3KO cells compared
toWTcontrols (Fig. 3C andD), thus suggesting a role for SIRT3 in
mitochondrial fusion.
ReducedOPA1 levels are known to cause decline inmitochon-
drial membrane potential (m), which can contribute to defects
in mitochondrial networking (43). Since our results showed that
acetylation reduced OPA1 activity, we posited that in SIRT3KO
cells OPA1 function may be defective in maintaining mitochon-
drial membrane potential. To test this possibility, TMRM (red)
uptake by mitochondria was monitored to measurem of adult
WT and SIRT3KO cells by live-cell videography. Cells overex-
pressed with mito-GFP (green) were utilized as a reference con-
trol. In the given time frame of the experiment, significantly large
numbers of depolarized mitochondria (green) were observed in
SIRT3KO cells, unlike the homogenous population seen in the
WT cells (Fig. 4A and B), thus suggesting that SIRT3 deficiency
leads to heterogeneous population ofmitochondria with defective
membrane potential. This finding further illustrated the role of
SIRT3 in regulating mitochondrial networking. These data are
consistent with an earlier study in which knockdown of SIRT3 in
hepatocytes caused loss of mitochondrial innermembrane poten-
tial with parallel elevation in ROS levels (44).
To test whether OPA1 is needed for SIRT3-mediated network-
ing of mitochondrial population, we monitored the mitochon-
drial morphology of WT or OPA1-null MEFs overexpressed with
Ad.mito-GFP orAd.SIRT3. As expected, a filamentousmitochon-
FIG2 SIRT3 binds to and deacetylatesOPA1. (A) Autoradiogram (uppermost panel) showing direct binding ofHis.OPA1 to 35S-labeled SIRT3 but not to SIRT5
in an in vitro binding assay. IBs confirm specificity of indicated proteins. (B) SIRT3 andOPA1 bind to each other when overexpressed in 293T cells. Proteins were
immunoprecipitated (IP) using Flag orMyc antibodies and immunoblotted (IB)with indicated antibodies. (C)Corresponding controls for panel B, showing that
myc-OPA1 does not cross-react with Flag beads (left panels) or that Flag-SIRT3 does not immunoprecipitate with c-myc (right panels). (D) Endogenous SIRT3
was coprecipitated withOPA1 fromWT and not from SIRT3KOhearts. (E) Reduced acetylation ofOPA1 immunoprecipitated fromHeLa stable cells expressing
SIRT3-WT, compared to SIRT3 HY mutant-expressing cells. (F) Reexpression of SIRT3 in SIRT3KO MEFs reduced OPA1 acetylation.
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drial network was observed in WT MEFs, whereas OPA1-null
MEFs had a highly fragmented mitochondrial population. SIRT3
overexpression in WT cells resulted in “intermediate” mitochon-
drial morphology (inset) or showed a perinuclear distribution of
fusedmitochondria (arrow); however, it failed to exhibit a similar
effect in OPA1-null MEFs (see Fig. S2A in the supplemental ma-
terial). These data suggested that the ability of SIRT3 to modulate
mitochondrial morphology is dependent on the presence of the
fusion protein OPA1. It also indicated that in these cells other
contributory factors of mitochondrial dynamics, such as fission
machinery, may not be altered by SIRT3. To further examine
whether SIRT3 needed OPA1 to manipulate mitochondrial
function, we measured ROS synthesis fromWT and OPA1-null
cells. Increased ROS production is linked to OPA1 mutations
in Drosophila (45). We overexpressed SIRT3 in OPA1-WT and
OPA1/ MEFs and subjected them to oxidative stress by treat-
ment with a sublethal dose of H2O2. With H2O2 treatment, ROS
levels increased both in OPA1-plus (WT) and -minus (null) cells
nearly 4-fold. SIRT3 overexpression reduced ROS to nearly con-
trol levels in WT cells but not as much in OPA1-null cells. These
data indicated that SIRT3 needs OPA1 as a downstream target to
maintain mitochondrial morphology and function (see Fig. S2B
in the supplemental material).
OPA1 is acetylated at Lys926 and Lys931 residues. To identify
SIRT3-targeted lysine (K) residues of OPA1, we subjected OPA1
prepared from SIRT3KO hearts to mass spectrometry (MS). The
results showed that OPA1 was acetylated at K926 and K931 in the
C-terminal GTPase effector domain (GED) (Fig. 5A; see Fig. S3A,
B, and C in the supplemental material). These lysine residues were
also acetylated when His.OPA-S1 was subjected to acetylation in
vitro using PCAF (see Fig. S4A and B in the supplemental mate-
rial). The OPA1-GED region, where these acetylated lysine resi-
dues are present, contains one of the coiled-coil domains neces-
sary for the formation of homotypic complex between different
OPA1 isoforms and is required for its role inmitochondrial fusion
(15, 46).
Loss of OPA1 is known to reduce the mitochondrial respira-
tion rate (13). Interestingly, reduced mitochondrial basal oxygen
consumption rate (OCR) is also reported for SIRT3KO skeletal
muscles (47) and hepatocytes (44). We therefore measured the
mitochondrial respiration rate to assess the functional signifi-
cance of OPA1 lysine acetylation. Acetylation neutralizes the pos-
itive charge on lysine (K). Replacement of K with R (arginine)
conserves the net positive charge and prevents charge neutraliza-
tion by acetylation and thus imitates the deacetylated state of the
protein. Conversely, a K-to-Q (glutamine) substitution resembles
FIG 3 SIRT3 regulates GTPase activity of OPA1 and mitochondrial fusion. (A) Bar diagram showing GTPase activity of acetylated OPA1, compared to
SIRT3-mediated deacetylated OPA1, as assessed by an in vitro enzymatic assay. GTP hydrolysis by His-OPA1.S1 protein was compared for indicated pretreat-
ments: nonacetylated (OPA1PCAF), acetylated (OPA1PCAFAcCoA), deacetylated (Ac.OPA1SIRT3NAD), and subjected to deacetylation in the
absence ofNAD (Ac.OPA1SIRT3NAD). Bars representmeans
 SEM, n 4. *,P 0.001. (B) Immunoblot shows acetylation status ofOPA1 and an equal
amount of protein used for the activity assay. (C) Reducedmitochondrial fusion in adult SIRT3KO cardiac fibroblasts as measured by diffusion of mtPA-GFP to
neighboring mitochondria, compared to WT controls. Total mitochondrial population was visualized by mtDSRed2 expression. Scale bar, 10 m. (D) Quan-
titation for mitochondrial networking factor (MNF) from the data acquired in the experiment shown in panel C. Means
 SEM are shown, n 20 events each.
AU, arbitrary units; *, P 0.001.
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constitutively acetylated lysine in terms of the charge. By site-
directed mutagenesis, we made R and Q retroviral mutants for
OPA1-K926 and K931 residues. These retroviruses (r) were used to
generate stable cell lines from immortalized OPA1-null MEFs.
Use of OPA1-null cells gave us the opportunity to assess the effect
of only the expressed isoform onmitochondrial function, without
interference from the endogenous OPA1. As a negative control,
we generated a stable line for K924 (r924R), which was not acety-
lated in SIRT3KO cells. The expression level of different OPA1
mutants is shown in Fig. 5B.We estimated the basal OCR for these
stable cells to evaluate the effect of OPA1-K926- and K931-specific
acetylation onmitochondrial respiration.Mitochondrial OCR for
wild-type and OPA1-null MEFs served as positive and negative
controls, respectively. Consistent with earlier reports (13), OPA1-
null MEFs had reduced basal OCR, compared to their WT coun-
terpart (Fig. 5C). OPA1-null MEFs stably expressing WT-OPA1
(rWT-OPA1) showed significantly improved basal OCR for null
cells (Fig. 5D). Stable cells expressing r926R and r931ROPA1 also
showed similar increase in basal OCR. On the other hand, the
r924ROPA1mutant was unable to elevate the OCR of OPA1-null
cells significantly compared to rWT-OPA1, which served as a neg-
ative control (Fig. 5D). These results highlighted the significance
of K926 and K931 residues in preserving the OPA1 function. The
effect of acetylation in these residues was determined by compar-
ing the ability of their respective R and Q mutants to improve
upon basal OCR of OPA1-null cells. The deacetylation-mimetic R
mutation had significantly higher OCR than the Qmutation, thus
implying that K926 and K931 residues play a role in acetylation-
mediated regulation of OPA1 function (Fig. 5E and F).
As an additional parameter to assess mitochondrial recovery,
we measured mitochondrial DNA copy number for these OPA1-
stable MEFs. Earlier studies have reported reduced SIRT3 levels
and reducedmtDNA content in diabetic patients (7, 48, 49). Sim-
ilarly, OPA1 mutations are linked to instability of mtDNA (50,
51).We observed significantly increasedmtDNAcopy numbers in
rWT, r926R, and r931R OPA1-expressing cells, compared to
OPA-nullMEFs.However, acetylation-mimetic r926Qand r931Q
mutants failed to restoremtDNAcopy number (see Fig. S5A in the
supplementalmaterial).We also checked the effect of the doubleR
and Q mutation on 926/931K residues (dmR- or dmQ-OPA) for
their ability to alter mitochondrial copy number. Overexpression
of the OPA1-dmR mutant significantly improved the mtDNA
content of OPA1-null cells, while the dmQmutant failed to do so
(see Fig. S5B andC in the supplementalmaterial). OPA1-null cells
overexpressed with WT-OPA1 (926/931K) served as a positive
control for mtDNA recovery. These data thus provided strong
evidence that reversible acetylation of 926K and 931K residues
regulate functions of OPA1.
One of the major functions ascribed to SIRT3 is its ability to
regulate mitochondrial ROS synthesis, thereby protecting cells
from oxidative damage. To know whether OPA1 can rescue mi-
tochondrial dysfunction of SIRT3KO cells, we measured ROS
production from cells as a readout of mitochondrial recovery.
SIRT3KO MEFs were overexpressed with OPA1-dmR or dmQ
mutants, and cellular ROS levels were measured. SIRT3KO cells
subjected to oxidative stress by H2O2 treatment showed a 4-fold
increase in ROS levels compared to those of untreated cells. Over-
expression of dmR-OPA1 but not the dmQ mutant significantly
reduced ROS levels of these cells (see Fig. S6A and B in the sup-
plementalmaterial). In this experiment, partial rescue from exces-
sive ROS generation in SIRT3KO cells by OPA1-dmR is likely due
to defective function of other enzymes involved in mitochondrial
ROS synthesis and detoxification (1). Nonetheless, these data fur-
ther suggested that SIRT3 regulates mitochondrial functions in
part by targeting OPA1.
SIRT3 expression modulates morphology of cardiac mito-
chondria. Knowing that OPA1 is one of the major regulators of
mitochondrial dynamics, we investigated how SIRT3-mediated
modulation of OPA1 could impact the morphology of cardiac
mitochondria. We performed ultrastructural studies for WT and
SIRT3KO adult hearts. Unlike the highly regular roadlike mito-
chondrial network seen for the adult WT heart (Fig. 6A),
SIRT3KO hearts displayed defective organization of mitochon-
dria. In SIRT3KO hearts, mitochondria were mostly clumped in
multiple islands (Fig. 6B). Moreover, unlike in WT hearts, mito-
chondria in SIRT3KO hearts showed a continuous outer mem-
brane but loosely tethered inner membranes (Fig. 6C and D).
Similar ultrastructural changes have been reported for OPA/
hearts (27), in which OPA1 protein expression is significantly re-
duced. Based on these findings and previous reports, it is reason-
able to believe that the mitochondrial defects observed in
SIRT3KO hearts result from reduced function of hyperacetylated
OPA1.
Anothermodel that we examined to study the impact of SIRT3
on mitochondrial morphology was doxorubicin (Dox)-mediated
cardiomyocyte cell death. Doxorubicin is a widely used anticancer
FIG 4 SIRT3KO cardiac fibroblasts exhibit loss of mitochondrial membrane
potential (m). (A) Still images over a time period of 5 min of WT and
SIRT3KO cardiac fibroblasts expressing mtGFP (green) and colabeled with
TMRM (red, appearing yellow whenmerged with green). In live videography,
lack and delay in the appearance of yellow mitochondria indicate a defect in
m. (B) Quantitation of depolarized mitochondria (ratio of TMRM-posi-
tive to total mitochondria) for the images shown in panel A. The data shown
are representative of four separate experiments. Scale bar, 5 m.
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drug that causes cardiac toxicity due tomitochondrial fragmenta-
tion and excessive ROS production (52, 53). Approaches aimed to
block mitochondrial fragmentation alleviate the cardiac toxicity
of this drug (54).Neonatal rat cardiomyocyteswere overexpressed
with either Ad.mito-GFP or Ad.SIRT3 followed by treatment with
Dox for 24 h. Mitochondrial morphology was monitored by con-
focal microscopy and cell death by TUNEL staining. Fragmented
and swollen mitochondria were seen in Dox-treated, Ad.mito-
GFP-expressing cardiomyocytes, whereas in Ad.SIRT3-express-
ing cells, even following Dox treatment, the normal tubular shape
of mitochondria was preserved (Fig. 7A). To examine whether
enzymatic activity of SIRT3 is needed for preservation of mito-
chondrial morphology after Dox treatment, we used stable HeLa
cells expressing SIRT3 WT or the HY mutant. As seen in Fig. 7B,
cells expressing SIRT3WT (middle right panel) showed preserved
mitochondrialmorphology afterDox treatment, but cells express-
ing catalytic mutant did not (bottom right panel). In control and
SIRT3 mutant-expressing cells, mitochondria were largely frag-
mented and swollen after Dox treatment, whereas the filamentous
morphology of mitochondria was preserved in SIRT3 WT-ex-
pressing cells. These data thus indicated that SIRT3 needs enzy-
matic activity to regulate mitochondrial morphology.
Experiments carried out to measure cell death in Dox-treated
cardiomyocytes demonstrated a marked reduction in TUNEL-
positive nuclei when overexpressed with SIRT3, compared to cells
expressedwith amock vector (Fig. 8A andB). The protective effect
of SIRT3 on Dox-treated cardiomyocytes was further supported
by results of Western analysis. Ad.SIRT3-expressing cardiomyo-
FIG 5 Oxygen consumption rate (OCR) for stable cells expressing OPA1 K mutants in OPA1-null MEFs. (A) Schematic representation of the OPA1 showing
locations of acetylated K 926 and K931 residues in the C-terminal GED region. (B) IB showing expression levels of OPA1 mutants in OPA1-null MEFs. (C) Bar
diagram depicting basal OCR for immortalized OPA1 WT and OPA1-null MEFs. Values are means 
 SEM; n  3; *, P  0.001. (D) OPA1-null MEFs were
expressed with retroviral vectors (r) synthesizingWT or OPA1 K-to-Rmutants. Bar diagram shows basal OCR for different cells. Values are means
 SEM; n
3; *, P 0.001. (E and F) Basal OCR of cells expressing K926 and K931 mutated to R or Q. Both K926Q and K931Q (acetylated form) have significantly lower
OCR than their respective R mutants. Bars represent means
 SEM; n 4; *, P 0.005.
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cytes showed reduced expression of cell death markers such as
Bax, Bim, and FasL compared to control virus-expressing cells
after Dox treatment (see Fig. S7 in the supplemental material).
Furthermore,Dox treatment of cardiomyocytes resulted in hyper-
acetylation of endogenous OPA1, which was reverted back by
overexpressing cells with SIRT3 (Fig. 8C). Taken together, these
data suggested that SIRT3 overexpression blocks Dox-mediated
mitochondrial fragmentation and subsequent cardiomyocyte cell
death by targeting OPA1.
DISCUSSION
In this study, we demonstrated a new role for SIRT3 as a regulator
of mitochondrial dynamics. SIRT3 targets the IM fusion protein
OPA1 to modulate its enzymatic activity via lysine deacetylation.
Our data demonstrated that mitochondrial respiration is differ-
entially affected depending upon the acetylation status of the two
lysine residues K926 and K931 residing in the C-terminal GED
region of OPA1. We found that these residues were acetylated
during cardiac hypertrophy and SIRT3 deficiency. We also
showed that SIRT3 deficiency impedes mitochondrial network-
ing, and overexpression of SIRT3 protects cells fromdoxorubicin-
mediated mitochondrial fragmentation and cell death. These
changes were associated with change in the acetylation status of
OPA1. Thus, in this study we demonstrated for the first time that
SIRT3 regulates mitochondrial dynamics by targeting OPA1 to
maintain fitness of mitochondrial population.
OPA1 is a functional target of SIRT3. In addition to matrix,
SIRT3 is also reported to be present at mitochondrial inner mem-
FIG 6 Transmission electron micrographs showing mitochondrial morphol-
ogy in SIRT3KO hearts. Electron micrographs showing mitochondrial mor-
phology and arrangement in adult wild-type (WT) (A and C) and SIRT3KO
hearts (B and D). SIRT3KO micrographs show mitochondria clustered in is-
lands (B). Arrows in SIRT3KOmicrographs (D) indicate defective mitochon-
drial inner membrane fusion. M, mitochondria; S, sarcomeres. Scale bars: 2
m (A and B); 1 m (C [left panel] and D [left top panel]); and 200 nm (C
[right panel] and D [bottom and right top panels]).
FIG 7 SIRT3 overexpression protects cells from doxorubicin-induced mito-
chondrial destruction. (A) Representative confocal images of cardiomyocytes
showing progressive deterioration ofmitochondria when treated with increas-
ing doses of doxorubicin (Dox). Mitochondria are visualized by overexpress-
ing cells withmito-GFP (green, upper panel). SIRT3 overexpression protected
the mitochondrial morphology of Dox-treated cardiomyocytes (red, lower
panel). Scale bar, 5 m. Insets display the mitochondrial morphology in an
enlarged image in each panel. (B) Unlike stable HeLa cells expressing SIRT3
catalyticmutant (bottompanel) or the vector (top panel),mitochondrialmor-
phology was preserved in SIRT3 WT-expressing cells when treated with Dox
(middle panel). Insets show mitochondrial morphology in enlarged images.
Scale bar, 1 m.
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brane and crista structures (55, 56). In this study, we found that
SIRT3 binds directly to the IM protein OPA1 and activates it by
deacetylation. Both OPA1 and SIRT3 are reported to regulate mi-
tochondrial respiration, ROS synthesis, and apoptosis (1, 24, 45,
57). SIRT3 is shown to regulate the oxidative phosphorylation
pathway by binding to and deacetylating the Ndufa9 subunit of
electron transport chain complex I (ETC-I) and succinate dehy-
drogenase subunit A (SdhA) of ETC-II (58, 59). Likewise, OPA1 is
reported to bind to ETC-I and -II (60). A correlation between
downregulation of OPA1, perturbation of crista structures, and
reduction in mitochondrial membrane potential is also reported,
indicating a potential role for OPA1 in the regulation of mito-
chondrial oxidative phosphorylation (24, 43). Same as for OPA1-
null cells, reduced basal OCR is also reported for SIRT3KO skel-
etal muscles (47) and hepatocytes (44). Consistent with these
reports, our data suggest that under conditions of stress, SIRT3
activates OPA1 to maintain and/or to enhance activity of mito-
chondrial respiratory complexes.
Mitochondria generate more than 90% of cellular ROS as a
by-product of mitochondrial respiration (61). Increased cellular
ROS levels are believed to contribute to many aging-associated
degenerative diseases (62). SIRT3 has been shown to block cardiac
hypertrophy and tumorigenesis by reducing ROS synthesis from
mitochondria (4, 6). Reduced activity of SIRT3 and increased mi-
tochondrial ROS synthesis are also reported in aging-associated
hearing loss (5). Likewise, OPA1 mutations are also linked to
hearing loss (63). Heterozygous mutations of Drosophila OPA1
(dOPA1) result in impairment of the ETC complexes’ activity and
increasedROSproduction (45). These dOPA1mutant flies show a
reduced life span, suggesting a similar role for OPA1 in regulating
longevity, as it is suggested for SIRT3 (8, 9, 45). Our data demon-
strated that SIRT3 can downregulate H2O2-induced ROS levels
more efficiently in the presence of OPA1 than in its absence. Sim-
ilarly, we could significantly reduce ROS generated by SIRT3KO
MEFs subjected to oxidative stress by overexpressing the deacety-
lation-mimeticOPA1 926/931Rmutant, thus highlighting the im-
portance of OPA1 as a potential downstream target of SIRT3.
A protective role of SIRT3 to curtail mitochondrially mediated
apoptosis has been demonstrated in cardiomyocytes (34, 64). In
mitochondrion-dependent apoptosis, cytochrome c release from
the inner mitochondrial space to cytosol requires remodeling of
crista junctions (65, 66). There are many reports showing that
OPA1 oligomers are the building blocks of the crista structures
(23). Reduced levels of OPA1 lead to disruption of crista struc-
tures and consequently apoptosis (24). OPA1mutants lacking the
functional GTPase domain or the C-terminal GED region sensi-
tize cells to death stimuli (23, 67, 68). In our study, the acetylated
lysine residues targeted by SIRT3 are uniquely positioned in the
GED region of OPA1. Our findings obtained by using Dox-medi-
ated cell death as a model system indicated that deacetylation of
OPA1 via SIRT3 could be one of the mechanisms through which
SIRT3 blocks mitochondrion-mediated apoptosis.
Role of OPA1 acetylation in cardiac hypertrophy. All the
mouse models for cardiac hypertrophy used in this study are
linked to mitochondrial dysfunction (47, 69–71), and each
showed hyperacetylated OPA1. Our study also demonstrated that
hyperacetylation reduces OPA’s GTPase activity, suggesting that
defective OPA1 could be a cause of mitochondrial dysfunction in
hypertrophied hearts. Consistent with our results, the adult
haplo-insufficient OPA1 heterozygous mice display normal car-
diac functions at rest; however, they are highly sensitive to hyper-
trophic stimuli, same as for SIRT3KOmice (28). OPA1/ hearts
also had clustered mitochondria with delayed opening of mito-
chondrial permeability transition pores (mPTP) after Ca2 stim-
ulation, compared to wild-type controls. OPA1 heterozygous
mice also developed late-onset cardiomyopathy with characteris-
tics largely resembling those of cardiomyopathy seen in SIRT3KO
mice under stress or with aging (28, 42).
Additionally, there is evidence showing a role for both SIRT3
and OPA1 in the development of metabolic stress and diabetes
(47, 72, 73). In the ob/obmouse model, before the onset of type 2
diabetes, a reduced level ofOPA1 is seen in pancreatic islets, which
contributes to mitochondrial dysfunction (72). Conditional
OPA1 knockout in the pancreatic beta cells also showed reduced
expression and activity of ETC-IV (73). Similarly, treatment of
cardiomyocytes with high glucose levels is reported to cause re-
duction in OPA1 level, enhanced mitochondrial fragmentation,
and diminished activity of ETC-IV (74). In accordance with this,
both in type 1 and in type 2 models of diabetes, SIRT3 expression
is reduced, which is linked to dysfunctional mitochondria (47).
These previous reports support our data presented here, which
unravel a new mechanism of action for SIRT3 whereby SIRT3
seems to preserve mitochondrial fitness by deacetylation and ac-
tivation of OPA1.
In humans andmouse, OPA1 protein exists as a complex mix-
ture of isoforms derived from its eight splice variants (46, 75–77).
FIG 8 SIRT3 expression protects cells from doxorubicin-mediated cell death.
(A) Cell death monitored by TUNEL (green) staining for cardiomyocytes
overexpressing either adenoviral vector (Ad.Vector) or SIRT3-adenovirus
(Ad.SIRT3) and treated with doxorubicin or vehicle for 24 h. Nuclei are
marked with DAPI staining (blue). Scale bar, 10 m. (B) Quantification of
TUNEL-positive cells shown in panel A. Values are means 
 SEM, n  4. *,
P  0.001. (C) IB showing acetylated OPA1 immunoprecipitated from neo-
natal rat cardiomyocytes treated with 300 nM doxorubicin. The right lane
shows that overexpressed SIRT3 binds to and deacetylates endogenous OPA1.
Veh., vehicle; vect., vector.
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In our study, retroviral overexpression of OPA1 deacetylation
mimic (K-to-R) isoforms could restore the basal OCR and
mtDNA copy number of OPA-null cells but not the acetylation
mimic (K-to-Q) mutants. Consistent with our results, a marked
reduction in mtDNA copy number and defects in mitochondrial
respiration concomitant with reduction in OPA1 activity were
reported earlier (27). Because the retroviral stable cells used in our
study were generated from OPA1-null cells, which lacked OPA1
isoforms normally synthesized from the genomic copy as splice
variants, we could not determine the effects of OPA1 K926R and
K931R mutants on the fusion ability of mitochondria in OPA1-
stable cells. Previous studies have reported that expression of var-
ious long and short isoforms of OPA1 in optimum combinations
are essential to reinstate all the functional capabilities of this en-
zyme (35, 36). Such kinds of combinations of OPA isoforms can-
not be expected in our cells, which were overexpressed with just
one isoform. This is one of the obvious difficulties in studying the
effect of PTM on the function of OPA to regulate mitochondrial
fusion.
The GTPase effector domain (GED) at the C terminus is pre-
dicted to regulate self-assembly of OPA1 and activation of GTP
hydrolysis (68). Mitochondrial morphology is reported to be de-
pendent on the integrity of this C-terminal coiled-coil domain of
OPA1 (15). The two acetylated lysine residues (926 and 931) of
OPA1 identified in our study reside in this GED region and are
likely to enhance GTPase activity of OPA1 upon deacetylation by
SIRT3. Deletion of the OPA1-GED region (OPA158) in type I
autosomal dominant optic atrophy (ADOA) patients results in
50% percent reduction in the OPA1 protein level, with increased
sensitivity to apoptosis (68). In hereditary optic atrophy patients,
9% of the OPA1 mutations, including the infamous R932C mu-
tation, are in the GED region (68). The R932Cmissense mutation
in OPA1 is associated with a large population of shorter mito-
chondria displaying defects in coupling of oxidative phosphoryla-
tion in skin fibroblasts of patients (78). By the same token, our
data suggest that under stress conditions GTPase activity of OPA1
may diminish with the addition of a bulky acetyl group on lysine
residues (931K and 926K) neighboring R932. Hence, it will be
beneficial for the cell to keep these lysine residues deacetylated.
Previously, it was reported that a lysine-to-alaninemutation in the
Drp1-GED region reduced GTPase activity of Drp1 (79). It will be
of future interest to study whether acetylation can affect the inter-
action betweenmitochondrial membrane lipids andOPA1 to reg-
ulate its catalytic activity. Basal GTPase activity of OPA1 is re-
ported to increase dramatically by its interaction with the
mitochondrial IM lipid cardiolipin (36). In summary, our data in
this study provide evidence that OPA1 activity is regulated by
reversible lysine acetylation and that SIRT3 promotes OPA1 ac-
tivity to fine-tune mitochondrial dynamics during cellular stress.
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